Pemetrexed in malignant pleural mesothelioma and the clinical outcome
The Clinical Respiratory Journal, 04/27/2012
Knuuttila A et al. – Pemetrexed is beneficial for selected patients, but it has not changed the outcome of the whole malignant pleural mesothelioma population as much as perhaps anticipated. Patient groups with various treatments or symptomatic care only reached survival results comparable to those reported in chemotherapy trials, thus emphasising the need for better subtyping of mesothelioma and individualising the treatment.